Skip to content

Public FDA record

Z-0702-2020: NATRELLE Resterilizable Sizers for the styles and sizes: Style 15, Style 20, Inspira X (responsive gel),

Recall record Z-0702-2020 for Allergan PLC. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0702-2020
Company in FDA record
Allergan PLC
FDA record creation date
Dec 18, 2019
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class III

Reason stated in the source

The firm has became aware that 2D barcodes on breast implants and sizers may be unreadable by GS-1 configured scanners. These 2D barcodes contain a group separators between fixed-length element string in the UDI data chain of the 2D barcode, which is not formatted to the GS1 standard.

Source facts

Action
Allergan sent out the field notification to consignees via email on 11/06/19. For consignees whom email was unavailable, a field notification letter was sent via overnight mail with tracking to all consignees.In addition to informing them about the correction, the notification requested consignees do the following: 1. You may continue to use these products. If your facility uses GS-1 configured scanners and the 2D barcode cannot be scanned, the UDI information can be entered manually by using the human readable information that appears next to the 2D barcode.: 1. To enter the UDI, For the example below, the complete UDI would be: (01) 10888628004221 (17) 20220512 (21) 23260389. 2. Verify the number was entered correctly. 3. If you received this as an email and did not provide a read receipt, please response directly to this email to confirm receipt. If you received this as a letter, please return the enclosed confirmation card. Your confirmation is an important part of our record keeping. 4. YOU DO NOT NEED TO RETURN ANY PRODUCT. 5. If you require further information or assistance, please contact Allergan Medical Information at 1-800-678-1605, Option 2 or IR-Medcom@allergan.com. To report product complaints, please contact Allergan Product Surveillance at 1-800-624-4261. 6. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDAs MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
Initiated
2019-11-06
Root cause
Error in labeling
Terminated
2021-07-09
Distribution
US:AL, AR,AZ,CA,CO,DC,FL,GA,HI,IA,ID,IL,IN,KS,KY,LA,MA,MD,ME,MI,MN,MO,MS,MT,NC,ND,NE,NH,NJ,NM,NV,NY,OH,OK,OR,PA,PR,RI,SC,SD,TN,TX,UT,VA,WA,WI,WY
Recall number
Z-0702-2020
Recall status
Terminated
CDRH record ID
178039
FDA record created
2019-12-18
Recall event number
84318

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗